Open AccessSevere enterocolitis secondary to ipilimumab and nivolumab with an excellent response to a single dose of infliximab
Author(s) -
A M Luque Carmona,
Guillermo Ontanilla-Clavijo,
Eduardo Leo Carnerero
Publication year - 2020
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2020.6886/2020
Subject(s) - medicine , nivolumab , infliximab , ipilimumab , enterocolitis , oncology , intensive care medicine , tumor necrosis factor alpha , cancer , immunotherapy
Immunotherapy is gaining significance in the management of oncological disease. It has demonstrated high levels of efficacy, though it also has hitherto unknown side effects, such as colitis. We present the first case of immune checkpoint inhibitor colitis (nivolumab+ipilimumab) refractory to corticoids treated in our hospital.